Raymond James Financial Services Advisors Inc. Raises Holdings in Boston Scientific Co. (NYSE:BSX)

Raymond James Financial Services Advisors Inc. grew its position in shares of Boston Scientific Co. (NYSE:BSX) by 3.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 507,550 shares of the medical equipment provider’s stock after purchasing an additional 14,723 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Boston Scientific were worth $29,341,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Bruce G. Allen Investments LLC purchased a new position in shares of Boston Scientific during the fourth quarter worth about $28,000. Coppell Advisory Solutions LLC acquired a new stake in Boston Scientific in the second quarter valued at about $34,000. Motco lifted its position in Boston Scientific by 136.3% in the third quarter. Motco now owns 645 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 372 shares during the period. Sunbelt Securities Inc. acquired a new stake in shares of Boston Scientific during the 1st quarter valued at approximately $32,000. Finally, Carolinas Wealth Consulting LLC lifted its position in shares of Boston Scientific by 2,174.2% during the 2nd quarter. Carolinas Wealth Consulting LLC now owns 705 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 674 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $66.35, for a total transaction of $463,322.05. Following the completion of the sale, the executive vice president now directly owns 53,788 shares of the company’s stock, valued at $3,568,833.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $66.35, for a total value of $463,322.05. Following the completion of the sale, the executive vice president now owns 53,788 shares in the company, valued at approximately $3,568,833.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jeffrey B. Mirviss sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $58.40, for a total transaction of $876,000.00. Following the completion of the sale, the executive vice president now owns 56,588 shares of the company’s stock, valued at approximately $3,304,739.20. The disclosure for this sale can be found here. Insiders sold a total of 76,460 shares of company stock valued at $4,759,945 over the last ninety days. Insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 16th. Mizuho upgraded Boston Scientific from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $65.00 to $80.00 in a research report on Thursday, February 1st. JPMorgan Chase & Co. lifted their price objective on Boston Scientific from $60.00 to $72.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Citigroup lifted their price objective on Boston Scientific from $65.00 to $71.00 and gave the stock a “buy” rating in a research report on Thursday, February 1st. Finally, Wells Fargo & Company upped their price target on shares of Boston Scientific from $70.00 to $72.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $66.62.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $68.62 on Thursday. Boston Scientific Co. has a fifty-two week low of $48.10 and a fifty-two week high of $68.66. The company has a market cap of $100.86 billion, a PE ratio of 64.13, a P/E/G ratio of 2.36 and a beta of 0.78. The firm has a 50-day simple moving average of $65.24 and a 200 day simple moving average of $58.05. The company has a quick ratio of 0.82, a current ratio of 1.32 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, beating the consensus estimate of $0.51 by $0.04. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. The business had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.59 billion. During the same period in the prior year, the business earned $0.45 earnings per share. On average, sell-side analysts anticipate that Boston Scientific Co. will post 2.25 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.